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Bias in published cost effectiveness studies: systematic review
Chaim M Bell, David R Urbach, Joel G Ray, Ahmed Bayoumi, Allison B Rosen, Dan Greenberg, Peter J Neumann
Abstract
Objective To investigate if published studies tend to report
favourable cost effectiveness ratios (below $20 000, $50 000,
and $100 000 per quality adjusted life year (QALY) gained) and
evaluate study characteristics associated with this phenomenon.
Design Systematic review.
Studies reviewed 494 English language studies measuring
health effects in QALYs published up to December 2001
identified using Medline, HealthSTAR, CancerLit, Current
Content, and EconLit databases.
Main outcome measures Incremental cost effectiveness ratios
measured in dollars set to the year of publication.
Results Approximately half the reported incremental cost
effectiveness ratios (712 of 1433) were below $20 000/QALY.
Studies funded by industry were more likely to report cost
effectiveness ratios below $20 000/QALY (adjusted odds ratio
2.1, 95% confidence interval 1.3 to 3.3), $50 000/QALY (3.2, 1.8
to 5.7), and $100 000/QALY (3.3, 1.6 to 6.8). Studies of higher
methodological quality (adjusted odds ratio 0.58, 0.37 to 0.91)
and those conducted in Europe (0.59, 0.33 to 1.1) and the
United States (0.44, 0.26 to 0.76) rather than elsewhere were
less likely to report ratios below $20 000/QALY.
Conclusion Most published analyses report favourable
incremental cost effectiveness ratios. Studies funded by industry
were more likely to report ratios below the three thresholds.
Studies of higher methodological quality and those conducted
in Europe and the US rather than elsewhere were less likely to
report ratios below $20 000/QALY.
Introduction
Cost effectiveness analysis can help inform policy makers on
better ways to allocate limited resources.1–3 Some form of cost
effectiveness is now required for health interventions to be cov-
ered by many insurers.1 4 5 The quality adjusted life year (QALY)
is used to compare the effectiveness of a wide range of interven-
tions. Cost effectiveness analysis produces a numerical ratio—the
incremental cost effectiveness ratio—in dollars per QALY. This
ratio is used to express the difference in cost effectiveness
between new diagnostic tests or treatments and current ones.
Interpreting the results of cost effectiveness analysis can be
problematic, making it difficult to decide whether to adopt a
diagnostic test or treatment. The threshold for adoption is
thought to be somewhere between $20 000 (£11 300, €16 500)/
QALY and $100 000/QALY, with thresholds of $50-60 000/
QALY frequently proposed.6–9
Regardless of the true value of the willingness of society to
pay, studies of healthcare interventions would be expected to
report a wide range of incremental cost effectiveness ratios.
When published ratios cluster around a proposed threshold, bias
may exist, and health policies based on their values may be
flawed.
To describe the distribution of reported incremental cost
effectiveness ratios and characteristics of studies associated with
favourable ratios, we systematically reviewed cost effectiveness
studies in health care that used QALYs as an outcome measure.
We hypothesised that authors tend to report favourable
incremental cost effectiveness ratios, such as those below
$50 000 per QALY.
Methods
We conducted a systematic literature search of Medline, Health-
STAR, CancerLit, Current Contents Connect (all editions), and
EconLit databases for all original cost effectiveness analyses
published in English between 1976 and 2001 that expressed
health outcomes in QALYs.10–13 Cost effectiveness analyses are
reported as dollars per QALY.1 We used a standard data
collection form, and two reviewers independently evaluated each
study and abstracted the data. Disagreements were resolved by
consensus. Details of the Tufts-NEMC CEA Registry (formerly
the Harvard School of Public Health CEA Registry) are available
online (http://tufts-nemc.org/cearegistry).
For each article, we documented the name of the journal, the
year of publication, the disease category, and the country where
the study was carried out. We used the Science Citation Index
database to assign an impact factor for the year before
publication to each journal. The sources of funding were identi-
fied as “industry” (partial or complete funding by a pharmaceu-
tical or medical device company indicated in the manuscript) or
“non-industry.” Studies for which a funding source was not listed
were identified as “not specified.”We also assigned a quality score
to each article, ranging from 1 (low) to 7 (high), based on the
overall quality of the study methods, assumptions, and reporting
practices.10
Because cost effectiveness analyses often compare several
programmes and include scenarios specific to patient subgroups
or settings, each study may have contributed more than one cost
effectiveness ratio. All cost effectiveness ratios were converted to
US dollars at the exchange rate prevalent in the year of publica-
tion.14 Because we wanted to test whether the ratios targeted cer-
tain thresholds of the willingness of society to pay, such as
$50 000/QALY, we did not adjust the ratios to constant dollars.
Statistical analysis
We analysed the distribution of all incremental cost effectiveness
ratios and of the smallest and largest ratios from each study. We
excluded nine ratios for which both the incremental cost and the
incremental QALYs were negative. Although such interventions
may be economically efficient, decision makers might not want
to adopt interventions associated with reduced health.15
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Generalised estimating equations were used to evaluate study
characteristics associated with incremental cost effectiveness
ratios below the threshold values of $20 000, $50 000, and
$100 000, as recommended previously.6 8 9 We used these
equations because they take into account the correlation of cost
effectiveness ratios derived from within the same study.16 We esti-
mated odds ratios for associations between study characteristics
and the presence of a favourable cost effectiveness ratio.
Adjusted odds ratios were estimated by fitting a non-
parsimonious model that included a priori predictor variables.
We used SAS statistical software version 8.2 for all analyses.
Two sided P values less than 0.05 were considered significant.
Results
We screened more than 3300 study abstracts and identified 533
original cost-utility analyses. Thirty nine studies were excluded
because they did not report numerical incremental cost
effectiveness ratios. In total, 1433 cost effectiveness ratios were
reported in these 494 studies, with a median of 2.0 (interquartile
range 1-3) and a range of 1-20 ratios per study. Overall, 130
incremental cost effectiveness ratios (9%) were reported as cost
saving (they saved money and improved health simultaneously),
124 (9%) were dominated by their comparators (had worse
health outcomes and increased costs), and 1179 (82%) increased
costs but improved health outcomes.
Most studies were published in the 1990s (table 1). The cita-
tion impact factor in the year before publication was available for
449 studies (91%). Cardiovascular and infectious disease
interventions were the most commonly studied. Most studies
were from the United States. About 18% were sponsored by
industry, almost half were sponsored by non-industry sources,
and sponsorship could not be determined in 34% of studies.
Figure 1 shows the frequency distribution of all 1433
incremental cost effectiveness ratios. The median (interquartile
range) ratio per QALY was $20 133 ($4520-74 400). Approxi-
mately half of the ratios (712; 50%) were below $20 000/QALY,
two thirds (974; 68%) were below $50 000/QALY, and more
than three quarters (1129; 79%) were below $100 000/QALY.
When analysed according to study sponsorship, median (range)
ratios per QALY were $13 083 ($3600-33 000) for those
sponsored by industry and $27 400 ($4600–96 600) for those
with non-industry sponsors. The median (range) cost effective-
ness ratio per QALY for studies with unknown sponsorship was
$18 900 ($4 960–64 300). Restricting the analysis to the lowest
and highest ratios reported by each study yielded median ratios
of $8784/QALY and $31 104/QALY (fig 2).
Several study characteristics were associated with reporting
incremental cost effectiveness ratios below one or all three
thresholds (table 2). The more quoted journals with a citation
impact factor above 4 were less likely to publish ratios below
$20 000/QALY (crude odds ratio 0.60, 95% confidence interval
0.42 to 0.86) or $50 000/QALY (crude 0.56, 0.38 to 0.82) than
less quoted journals with a lower impact factor. However, this
finding was not significant within the multivariable model (table
2).
Studies funded by industry were more likely to report cost
effectiveness ratios less than $20 000/QALY (adjusted odds ratio
2.1, 1.3 to 3.3), $50 000/QALY (3.2, 1.8 to 5.7), or
$100 000/QALY (3.3, 1.6 to 6.8) than studies funded by
non-industry sources (table 2). Studies carried out in the US and
Europe were significantly less likely to find favourable incremen-
tal cost effectiveness ratios than studies carried out elsewhere.
Studies with quality scores for methodology above 5.5 were sig-
nificantly less likely to report ratios below $20 000/QALY (0.48,
0.33 to 0.70) and $50 000/QALY (0.57, 0.39 to 0.83). Within the
multivariable model, the association with quality remained
significant only for cost effectiveness ratios below $20 000/
QALY (adjusted odds ratio 0.58, 0.37 to 0.91; table 2).
Discussion
About half of all cost effectiveness studies published over a 25
year period reported highly favourable incremental cost
Table 1 Characteristics of 494 cost-utility analyses of health interventions
published between 1976 and 2001
Study characteristic No. (%)
Publication year
1976-91 47 (9)
1992-6 125 (25)
1997-2001 322 (65)
Journal impact factor*
<2 157 (32)
2-4 137 (28)
>4 155 (31)
Not available 45 (9)
Disease category
Cardiovascular 110 (22)
Endocrine 30 (6)
Infectious 94 (19)
Musculoskeletal 21 (4)
Neoplastic 76 (15)
Neurological or psychiatric 43 (9)
Other 120 (24)
Sponsorship or funding source
Non-industry 240 (49)
Industry† 88 (18)
Not specified 166 (34)
Region of study
Europe 118 (24)
United States 306 (62)
Other‡ 70 (14)
Methodological quality§
1.0-4.0 214 (43)
4.5-5.0 159 (32)
5.5-7.0 121 (25)
*Impact factor for that journal in the year before publication of the study.
†Funding by a pharmaceutical or medical device manufacturer.
‡Canada 41 (59%), Australia 18 (26%), Japan 2 (3%), New Zealand 2 (3%), South Africa 2
(3%), other 5 (7%).
§Mean quality scores for the two reviewers.
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Fig 1 Frequency distribution of 1433 incremental cost effectiveness ratios for
health interventions
Research
page 2 of 5 BMJ Online First bmj.com
effectiveness ratios of less than $20 000/QALY. More than half
of the highest ratios reported by each study were below
$50 000/QALY. In multivariable analysis, location of the study,
methodological quality, and sponsorship were associated with a
favourable cost effectiveness ratio. Studies sponsored by industry
were more than twice as likely as studies sponsored by
non-industry sources to report ratios below $20 000/QALY and
over three times more likely to report ratios below $50 000/
QALY or $100 000/QALY. Studies sponsored by industry were
also more likely to be of lower methodological quality and to be
published in journals with lower impact factors.
Few studies have described the distribution of reported
incremental cost effectiveness ratios.12 17 We reviewed many stud-
ies, but we restricted our analysis to studies that measured health
outcomes with QALYs. Although the QALY measure remains
controversial, it has been endorsed by authoritative bodies, and it
potentially allows cost effectiveness analysis to assess both
allocative and technical efficiency.1 18 19 It would be interesting to
examine whether the use of alternative measures of health
outcome results in more or less favourable cost effectiveness
ratios. A limitation of our analysis is that some cost effectiveness
analyses used in decision making may not have been published.5
However, analyses of cost effectiveness assessments submitted to
the National Institute for Health and Clinical Excellence (NICE)
in the United Kingdom found that cost effectiveness ratios sub-
mitted by manufacturers were significantly lower than analyses
of identical technologies performed by assessors from an
academic centre.20
Publication bias
We found relatively few published incremental cost effectiveness
ratios between $50 000/QALY and $100 000/QALY; many
were below $20 000/QALY and some were above $100 000/
QALY. This indicates that cost effectiveness analyses tend to
report “positive” or “negative” results but not intermediate
results. There are three possible explanations for these findings.
Firstly, they may reflect the true distribution of cost effectiveness
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Table 2 Characteristics of studies associated with favourable incremental cost effectiveness ratios according to three threshold values. Values are odds ratios
(95% confidence intervals)
Study characteristic
Crude OR (95% CI) Adjusted OR (95% CI)*
<$20 000/QALY <$50 000/QALY <$100 000/QALY <$20 000/QALY <$50 000/QALY <$100 000/QALY
Publication year
1976-91 1.6 (0.98 to 2.7) 1.4 (0.80 to 2.4) 1.2 (0.67 to 2.3) 1.6 (0.96 to 2.7) 1.3 (0.76 to 2.3) 1.2 (0.61 to 2.2)
1992-6 1.3 (0.94 to 1.9) 1.4 (0.93 to 2.3) 1.1 (0.68 to 1.6) 1.3 (0.87 to 1.8) 1.3 (0.87 to 1.9) 1.0 (0.64 to 1.6)
1997-2001 1.0 1.0 1.0 1.0 1.0 1.0
Journal impact factor†
<2 1.0 1.0 1.0 1.0 1.0 1.0
2-4 0.62 (0.42 to 0.91) 0.62 (0.41 to 0.94) 0.59 (0.38 to 0.94) 0.75 (0.50 to 1.1) 0.82 (0.53 to 1.3) 0.77 (0.47 to 1.2)
>4 0.60 (0.42 to 0.86) 0.56 (0.38 to 0.82) 0.83 (0.53 to 1.3) 0.95 (0.63 to 1.4) 0.81 (0.52 to 1.3) 1.1 (0.66 to 1.9)
Disease category
Cardiovascular 1.0 1.0 1.0 1.0 1.0 1.0
Endocrine 1.3 (0.68 to 2.6) 1.2 (0.58 to 2.5) 1.3 (0.58 to 3.0) 1.2 (0.56 to 2.4) 1.1 (0.52 to 2.3) 1.2 (0.53 to 2.7)
Infectious 1.1 (0.66 to 1.7) 0.79 (0.48 to 1.3) 0.74 (0.43 to 1.3) 1.0 (0.64 to 1.7) 0.75 (0.44 to 1.3) 0.71 (0.39 to 1.3)
Musculoskeletal 1.4 (0.60 to 3.3) 1.3 (0.51 to 3.1) 1.4 (0.50 to 3.7) 1.1 (0.43 to 2.7) 0.89 (0.34 to 2.3) 1.1 (0.37 to 3.1)
Neoplastic 0.91 (0.56 to 1.5) 0.79 (0.46 to 1.3) 0.77 (0.42 to 1.4) 0.78 (0.47 to 1.3) 0.64 (0.37 to 1.1) 0.69 (0.36 to 1.3)
Neurological/psychiatric 0.76 (0.40 to 1.5) 0.78 (0.40 to 1.5)) 0.66 (0.31 to 1.4) 0.75 (0.39 to 1.4) 0.70 (0.34 to 1.4) 0.61 (0.27 to 1.4)
Other 1.2 (0.75 to 1.8) 0.67 (0.42 to 1.1) 0.52 (0.31 to 0.88) 1.0 (0.63 to 1.6) 0.53 (0.31 to 0.88) 0.49 (0.27 to 0.86)
Study funding source‡
Non-industry 1.0 1.0 1.0 1.0 1.0 1.0
Industry 2.2 (1.4 to 3.4) 3.5 (2.0 to 6.1) 3.4 (1.6 to 7.0) 2.1 (1.3 to 3.3) 3.2 (1.8 to 5.7) 3.3 (1.6 to 6.8)
Not specified 1.3 (0.95 to 1.9) 1.5 (1.1 to 2.2) 1.4 (0.93 to 2.1) 1.3 (0.89 to 1.8) 1.5 (1.0 to 2.1) 1.5 (0.97 to 2.2)
Region of study
Europe 0.50 (0.28 to 0.89) 0.43 (0.21 to 0.87) 0.46 (0.21 to 1.0) 0.59 (0.33 to 1.1) 0.42 (0.21 to 0.86) 0.43 (0.19 to 0.96)
United States 0.35 (0.21 to 0.57) 0.29 (0.16 to 0.55) 0.33 (0.16 to 0.66) 0.44 (0.26 to 0.76) 0.35 (0.18 to 0.67) 0.33 (0.16 to 0.68)
Other§ 1.0 1.0 1.0 1.0 1.0 1.0
Methodological quality¶
1.0-4.0 1.0 1.0 1.0 1.0 1.0 1.0
4.5-5.0 0.92 (0.64 to 1.3) 0.95 (0.64 to 1.4) 0.96 (0.62 to 1.5) 1.0 (0.70 to 1.5) 1.1 (0.70 to 1.6) 1.0 (0.63 to 1.6)
5.5-7.0 0.48 (0.33 to 0.70) 0.57 (0.39 to 0.83) 0.82 (0.52 to 1.3) 0.58 (0.37 to 0.91) 0.72 (0.45 to 1.2) 0.90 (0.51 to 1.6)
QALY, quality adjusted life year.
*Adjusted for all other study characteristics.
†Impact factor in the year before publication.
‡Funding by a pharmaceutical or medical device manufacturer.
§Canada 41 (59%), Australia 18 (26%), Japan 2 (3%), New Zealand 2 (3%), South Africa 2 (3%), other 5 (7%).
¶Mean score from two reviewers.
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ratios for healthcare interventions. Perhaps interventions that
manufacturers deem to be economically unattractive are not
brought to market.21 Secondly, analysts may not be interested in
studying interventions with mid-range cost effectiveness ratios or
some journals may not want to publish such studies. Thirdly,
some cost effectiveness analyses may be modelled to yield
favourable ratios or studies with unfavourable ratios may be sup-
pressed. These findings do not tell us whether authors (and their
sponsors) fail to report undesirable cost effectiveness results
while reporting those that are positive. It is unclear whether pub-
lication bias occurs at a conscious or unconscious level. In any
case, our results support concerns about the presence of signifi-
cant and persistent bias in both the conduct and reporting of
cost effectiveness analyses.22 23 It could be argued that all cost
effectiveness analyses should be registered before they start, as
for randomised clinical trials, but this may be unrealistic given
the way they are currently conducted.24
If bias is an important explanation for our findings, our
results indicate that the “target” cost effectiveness ratio for a
healthcare intervention is between $20 000/QALY and
$50 000/QALY. The true willingness of society to pay for an
extra QALY is unknown, although some have tried to derive this
willingness from economic principles, or to infer it from policy
level decisions.25–27 In the US, the threshold most often used is
$50 000/QALY, based on Medicare’s coverage of dialysis,
although the criteria for selecting this value have been
criticised.8 26 Furthermore, interventions may be adopted despite
having an unfavourable ratio if other concerns such as disease
burden and health equity are dealt with.25
Recent attempts to standardise the conduct and reporting of
economic analyses and modelling studies may help prevent the
manipulation of studies.1 18 28–30 Such guidelines offer the produc-
ers of cost effectiveness analyses, reviewers, readers, and journal
editors a framework against which they can assess analyses,
although the complexity of models and publication bias remain
important issues.5 8 22 Electronic publishing could enhance trans-
parency in modelling by making technical appendices available
and improving the presentation of results.3 23 Furthermore,
distribution of the underlying decision analysis models to the
public should be considered.
Industry sponsorship and the location of the study do not
fully explain the tendency for incremental cost effectiveness
ratios to fall below desirable thresholds. Fewer than 20% of stud-
ies reviewed were funded by industry, and another 33% did not
specify their source of funding. Moreover, the median ratio for
studies not sponsored by industry was well below the
$50 000/QALY threshold. The lower ratios found in US studies
cannot be fully accounted for by foreign exchange rates and
inflation because the US results were similar to those found in
European studies. The methodological quality of studies is
another factor that should be explored in future research.
Journal editors and reviewers can help reduce publication
bias.23 31–33 Potential conflicts of interest of study sponsors and
authors need to be scrutinised.23 34–36 One approach is to restrict
the publication of cost effectiveness analyses funded by industry
if at least one author has direct financial ties with the sponsoring
company, as adopted by the New England Journal of Medicine in
1994.37 Journal editors may show bias by publishing studies with
positive results but not studies with negative results, although this
practice may not be common.33 38–41 One study proposes that dif-
ferences between economic analyses cannot be explained by
selective submission or editorial selection bias alone and
probably reflect a more fundamental difference in the studies.42
Conclusions
More rigour and openness is needed in the discipline of health
economics before decision makers and the public can be
confident that cost effectiveness analyses are conducted and
published in an unbiased manner. These considerations are a
prerequisite for these analyses to compare health management
strategies. A heightened awareness of the limitations of cost
effectiveness analyses and potentially influential factors may help
users to interpret the conclusions of these analyses.
The paper was presented in abstract form at the Fifth International
Congress on Peer Review and Biomedical Publication in Chicago, IL, 16-18
September 2005.
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